Invasive fungal diseases (IFD) still cause substantial morbidity and mortality, and new therapeutic approaches are urgently needed. Recent data suggest a benefit of checkpoint inhibitors (ICI). We report the case of a diabetic patient with refractory IFD following a SARSCoV-2 infection treated by ICI and interferon-gamma associated with antifungal treatment.
CITATION STYLE
Serris, A., Ouedrani, A., Uhel, F., Gazzano, M., Bedarida, V., Rouzaud, C., … Lanternier, F. (2022). Case Report: Immune Checkpoint Blockade Plus Interferon-Γ Add-On Antifungal Therapy in the Treatment of Refractory Covid-Associated Pulmonary Aspergillosis and Cerebral Mucormycosis. Frontiers in Immunology, 13. https://doi.org/10.3389/fimmu.2022.900522
Mendeley helps you to discover research relevant for your work.